Latest Medical Devices News

OncoSil Medical has reported a record 20% quarterly increase in dose sales and secured $8.7 million in new capital, underpinning its clinical and commercial expansion in pancreatic cancer treatment.

SomnoMed reports a robust Q4 FY25 with 25% revenue growth and a milestone of treating over 1 million patients, while gearing up for significant capacity expansion and clinical advancements.

EMVision Medical Devices has secured ethics approvals for two pivotal clinical studies and received a $400,000 milestone payment, marking significant progress toward commercialising its portable First Responder brain scanner.

TruScreen Group Limited has announced a placement of over 1.7 million shares to settle marketing invoices and provide an equity incentive to its CFO, signaling strategic capital management ahead of its next growth phase.

PainChek Limited has raised A$7.5 million through a strongly supported placement to accelerate its US market entry following anticipated FDA clearance and expand its innovative AI pain assessment technology internationally.

Compumedics has secured two significant four-year distribution agreements in China worth A$24.4 million, reinforcing its strategic foothold in Asia with committed annual growth of at least 10%.

Imricor Medical Systems reported significant regulatory and commercial progress in Q2 CY25, including CE mark approvals and expanded clinical trials, while maintaining a strong cash position.

Universal Biosensors reports a $1.59 million improvement in operating cash outflows for Q2 2025, maintaining $2.55 million in cash as it advances commercialization across blood, wine, and water testing markets.

BTC Health has secured a $0.5 million order for its life-saving ECMO equipment from the Women's and Children's Hospital in Adelaide, marking a significant expansion of its specialised medical device network alongside Melbourne's Royal Children's Hospital.

Atomo Diagnostics has successfully placed $260,000 of the shortfall from its recent Share Purchase Plan, issuing over 14 million shares and options to sophisticated investors. This capital injection strengthens the company’s working capital position as it advances its rapid diagnostic test business.

PainChek has completed its final FDA submission for the PainChek Adult App, targeting the US long-term care market with a potential $100 million annual opportunity. A regulatory decision is expected within 75 days, setting the stage for rapid commercialisation.

EBR Systems has received preliminary approval from the U.S. Centers for Medicare & Medicaid Services for outpatient reimbursement of its WiSE® CRT System, marking a major step toward broader hospital adoption.